An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Conditions
Hematologic Malignancy · Solid Tumor · Advanced Malignancies
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California LA, Los Angeles, California, United States
Contact: Principal Investigator (Gary Schiller)Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Contact: Principal Investigator (Candido Rivera)Northwestern University, Chicago, Illinois, United States
Contact: Principal Investigator (Brady L Stein)Uni Of Michigan Health System, Ann Arbor, Michigan, United States
Contact: Principal Investigator (Moshe Talpaz)New York Presbyterian Hospital, New York, New York, United States
Contact: Principal Investigator (Joseph Scandura)Mt Sinai Medical Center, New York, New York, United States
Contact: Principal Investigator (Marina Kremyanskaya)Novartis Investigative Site, Antwerp, Belgium
Novartis Investigative Site, Bruges, Belgium
Novartis Investigative Site, Florence, FI, Italy
Novartis Investigative Site, Varese, VA, Italy
Novartis Investigative Site, Novara, Italy
Novartis Investigative Site, Amsterdam, Netherlands
Novartis Investigative Site, Cardiff, United Kingdom
Novartis Investigative Site, Glasgow, United Kingdom
Novartis Investigative Site, London, United Kingdom
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals